Primary splenic lymphoma discovered on massive splenomegaly: A case report.
Case report
Large B cell lymphoma
Massive splenomegaly
Splenectomy
Journal
International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
24
03
2022
revised:
24
04
2022
accepted:
24
04
2022
entrez:
5
6
2022
pubmed:
6
6
2022
medline:
6
6
2022
Statut:
ppublish
Résumé
Malignant lymphoma occurs in all the systemic organs. Rarely, large B-cell lymphoma is located in the spleen, making the diagnosis difficult. Herein, we report a patient presenting with massive splenomegaly due to LBCL. Splenectomy was essential to assess the diagnosis and to guide postoperative therapeutics. A 47-year-old woman, with no comorbidities, complained of weight loss and abdominal pain. She had a palpable spleen that extended below the navel. CT scan revealed massive splenomegaly and lymph nodes in the spleen hilum. Splenectomy was performed. Histopathological examination confirmed the diagnosis of large B-cell lymphoma. The postoperative course was uneventful. Three courses of chemotherapy were given. The patient was in remission after a follow-up of 8 months. Massive splenomegaly can be one of the circumstances of the discovery of large B-cell lymphoma. Splenectomy was then essential to confirm the diagnosis and to guide postoperative therapeutics. It also permits reducing hypersplenism and preventing spleen rupture. In patients with high operative risk, splenic needle biopsy should be taken into consideration. Splenic artery embolization before surgery can also be performed in patients having massive splenomegaly to reduce the spleen volume. We highlight the importance of splenectomy to confirm the diagnosis and to relieve the symptoms. Postoperative chemotherapy is essential to prevent relapses. Splenectomy is essential in spleen localized large B-cell lymphoma. It permits to confirm the diagnosis, relieve symptoms, and treatment of underlying hematologic malignancies. Postoperative chemotherapy is essential to prevent relapses.
Identifiants
pubmed: 35658295
pii: S2210-2612(22)00370-4
doi: 10.1016/j.ijscr.2022.107124
pmc: PMC9079000
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107124Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Open Forum Infect Dis. 2016 Sep 21;3(4):ofw197
pubmed: 27975073
Surg Endosc. 2008 Apr;22(4):821-48
pubmed: 18293036
Am J Surg. 2012 Apr;203(4):517-22
pubmed: 21924403
Rev Med Interne. 2010 Sep;31(9):615-20
pubmed: 20488592
Acta Haematol. 2008;119(2):83-8
pubmed: 18305380
World J Clin Cases. 2014 Sep 16;2(9):478-81
pubmed: 25232555
Surg Gynecol Obstet. 1965 May;120:947-60
pubmed: 14269844
Am J Surg Pathol. 2003 Jul;27(7):895-902
pubmed: 12826881
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):60-9
pubmed: 21215540
Int J Surg Case Rep. 2015;16:174-6
pubmed: 26479782
Am Surg. 1991 Feb;57(2):108-13
pubmed: 1992865
Haematologica. 1995 May-Jun;80(3):241-3
pubmed: 7672717
Int J Surg Case Rep. 2018;48:76-78
pubmed: 29885916
Intern Med. 2010;49(11):1027-30
pubmed: 20519821
ANZ J Surg. 2006 Aug;76(8):679-82
pubmed: 16916382
Int J Surg. 2020 Dec;84:226-230
pubmed: 33181358
J Vasc Interv Radiol. 2008 Jan;19(1):80-7
pubmed: 18192471